Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells 15,040 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director James R. Tobin sold 15,040 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $106.43, for a total value of $1,600,707.20. Following the sale, the director now directly owns 205,171 shares in the company, valued at approximately $21,836,349.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $127.99 on Friday. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $129.66. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87. The stock’s 50-day moving average is $85.54 and its two-hundred day moving average is $77.08.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. The firm had revenue of $96.90 million for the quarter, compared to the consensus estimate of $83.78 million. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. During the same quarter last year, the business posted ($0.08) EPS. The firm’s quarterly revenue was up 132.9% compared to the same quarter last year. Analysts predict that TransMedics Group, Inc. will post 0.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on TMDX shares. Canaccord Genuity Group upped their price target on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday. TD Cowen upped their target price on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday. Oppenheimer boosted their price target on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a report on Wednesday. Morgan Stanley lifted their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. Finally, JPMorgan Chase & Co. increased their target price on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average target price of $119.00.

Institutional Trading of TransMedics Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Harbour Capital Advisors LLC increased its holdings in shares of TransMedics Group by 1.7% in the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock valued at $627,000 after purchasing an additional 140 shares during the period. RiverPark Advisors LLC increased its stake in TransMedics Group by 19.5% in the 4th quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock valued at $104,000 after buying an additional 215 shares during the period. First Horizon Advisors Inc. increased its stake in TransMedics Group by 26.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after buying an additional 222 shares during the period. Park Avenue Securities LLC raised its position in TransMedics Group by 3.4% during the 1st quarter. Park Avenue Securities LLC now owns 11,374 shares of the company’s stock worth $841,000 after buying an additional 372 shares during the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in shares of TransMedics Group in the 1st quarter worth $30,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.